Domestic sales rise 1.7% for the quarter, while international sales jump 4.2%.
Diluted EPS +8.8% Y/Y.
Global consumer sales come in at $3.6B, up 2% Y/Y ex-currency impact.
Global pharmaceutical sales rise 10.9% (ex-currency impact) to $7B.
Worldwide medical devices sales of $6.9B rise slightly, but fall when adjusted for a negative currency impact of 2.3%.
FY13 EPS guidance raised to $5.44-5.49 from $5.40-5.47. Consensus is $5.46. (PR)